Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART

AIDS

Volumn 15, Issue 13, 2001, Pages 1635-1641

  Patterson, Bruce K ^a   McCallister, Scott ^b   Schutz, Malte ^b   Siegel, Joan N ^b   Shults, Keith ^c   Flener, Zareefa ^a   Landay, Alan ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c Esoterix Oncology   (United States)

Author keywords

Flow cytometry; Highly active antiretroviral therapy; Immune responsiveness; In situ hybridization; Viral load; Viral persistence

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD45 ANTIGEN; MESSENGER RNA; TETANUS TOXOID; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; RNA, MESSENGER; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 0035822946     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109070-00005     Document Type: Article

References (44)

1. Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation
2. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
3. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
4. Identification of a reservoir for HIV-1 in patients on HAART
5. Presence of an inducible HIV-1 latent reservoir during HAART
6. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
7. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy
8. Normalisation of immune activation in lymphoid tissue following potent antiretroviral therapy
9. Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV-1 disease
10. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
11. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection
12. Maximum suppression of HIV-1 replication leads to the restoration of HIV-l-specific responses in early HIV-1 disease
13. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
14. Vigorous HIV 1-specific CD4+T cell responses associated with control of viremia
15. Detection of HIV RNA positive monocytes in peripheral blood of HIV positive patients by simultaneous flow cytometric analysis of intracellular HIV RNA and cellular immunophenotype
16. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-l-Infected subjects on HAART plus an inactivated HIV-1 immunogen
17. In vivo migration and function of transferred HIV-1-specific cytotoxic T-cells
18. Productive infection of neonatal CD8+ T- lymphocytes by HIV-1
19. Infection of HIV-1 transgenic mice with Mycobacterium avium induces the expression of infectious virus selectively from a MAC-1-positive host cell population
20. Viral dynamics in HIV-1 infection
21. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, viral generation time
22. Decay characteristics of HIV-1 infected compartments during combination therapy
23. Kinetics of response in lymphoid tissue to antiretroviral therapy of HIV-1 infection
24. In vivo estimates of division and death rates of human T lymphocytes
25. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy
26. Negative result of cytomegalovirus blood culture with restoration of CD4+ T-cell reactivity to cytomegalovirus after HAART in an HIV-1infected patient
27. Frequency of class I HLA restricted anti-HIV-1 CD8+T cells in individuals receiving highly active antiretroviral therapy (HAART)
28. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
29. HIV-1-specific CD4+T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
30. A critical role of Tat and IFNα in the HIV-1 induced immunosuppression leading to AIDS
31. The N-terminal structure of HIV-1 tat is required for suppression of CD26-dependent T cell growth
32. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis and HIV-1 long terminal repeat transactlvation in purified CD4+T lymphocytes
33. HIV-1 Tat represses transcription of the beta 2-microglobulin promoter
34. Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus nef use distinct but overlapping target sites for downregulation of cell surface CD4
35. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
36. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest
37. Human immunodeficiency virus type 1 Vpr-medlated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A
38. Activation of virus replication after vaccination of HIV-1-infected individuals
39. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination
40. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
41. Enhancement of HIV-1 type 1 antigen-specific CD4+T cell memory in subjects with chronic HIV-1 type 1 infection receiving an HIV-1 type 1 immunogen
42. Control of HIV-1 despite the discontinuation of antiretroviral therapy
43. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
44. Generation of HIV latency during thymopoiesis